Law360, New York (August 21, 2007, 12:00 AM EDT) -- A drug wholesaler has sought treble damages in a putative class action lawsuit against Sanofi-Aventis, accusing the French pharmaceutical giant of unlawfully blocking generic competition for Sanofi's rheumatoid arthritis treatment Arava by filing a sham Citizen Petition with the U.S. Food and Drug Administration.
Louisiana Wholesale Drug Co. Inc. filed the lawsuit on Friday in federal court in Manhattan, against Sanofi-Aventis, Sanofi-Aventis US LLC and Aventis Pharmaceuticals Inc.
The drug at issue in the suit is leflunomide, which is sold under the brand name Arava. AB-rated...
Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.